We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

6699:HKEXAngelalign Technology Inc. Analysis

Data as of 2026-03-17 - not real-time

HK$70.50

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Angelalign trades around HK$70.5, comfortably above its support at HK$66 and below the recent high of HK$78.85. The stock shows a classic bullish SMA hierarchy (20‑day ≈ 72.84 > 50‑day ≈ 70.37 > 200‑day ≈ 64.13) and a bullish trend direction, yet the MACD is in a bearish crossover (line -0.23 vs signal 0.28) and the RSI sits near the mid‑range at 46.5, suggesting limited upside momentum. Valuation metrics are stark: a trailing PE of 64.7 far exceeds the industry average of 26.2, and the DCF‑derived fair value of roughly HK$10.5 implies the market is pricing the stock at a massive premium. Fundamentals reveal strong revenue growth (33% YoY) but thin operating margins (6%) and negative free cash flow, while the recent European court ruling on software features is expected to have minimal user impact, nevertheless it highlights a regulatory exposure. Combined with high 30‑day volatility (≈35.7%) and a moderate beta (~1.3), the stock appears overvalued and carries notable risk despite its growth narrative.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish SMA alignment supports near‑term stability
  • Bearish MACD crossover limits upward thrust
  • Current price near support with limited upside before hitting resistance at ~HK$77.45

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Revenue growth remains strong but margins are thin
  • Valuation still far above DCF fair value
  • Regulatory headwind from European software ruling adds uncertainty

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Severe overvaluation relative to peers and intrinsic value
  • Negative free cash flow and modest ROE (4.7%)
  • Elevated volatility and exposure to Chinese regulatory environment

Key Metrics & Analysis

Financial Health

Revenue Growth33.10%
Profit Margin7.64%
P/E Ratio64.7
ROE4.73%
ROA1.09%
Debt/Equity18.86
P/B Ratio3.2
Op. Cash FlowHK$53.0M
Free Cash FlowHK$-22444940
Industry P/E26.2

Technical Analysis

TrendBullish
RSI46.5
SupportHK$66.00
ResistanceHK$77.45
MA 20HK$72.84
MA 50HK$70.37
MA 200HK$64.13
MACDBearish
VolumeStable
Fear & Greed Index81.48

Valuation

Fair ValueHK$10.48
Target PriceHK$86.47
Upside/Downside22.65%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.02
Volatility35.71%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.